Literature DB >> 15961287

Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect.

Jill M Williams1, Douglas M Ziedonis, Francisca Abanyie, Marc L Steinberg, Jonathan Foulds, Neal L Benowitz.   

Abstract

It has been hypothesized that smokers with schizophrenia take in more nicotine per cigarette than smokers without this disorder. This study examines this phenomenon by comparing the serum nicotine and cotinine levels in smokers with either schizophrenia or schizoaffective disorder compared to control smokers without mental illness. Serum cotinine and nicotine levels of smokers with schizophrenia or schizoaffective disorder were 1.3 times higher than control smokers (cotinine 291 versus 227 ng/mL; p = 0.0115; nicotine 28 versus 21 ng/mL; p < 0.001) despite smoking a similar number of cigarettes per day. Similar serum 3'-hydroxycotinine (3HC) to cotinine ratios in both groups indicate that this difference was not due to differences in the rate of metabolism of nicotine or cotinine. By examining serum nicotine and 3HC/cotinine ratios in addition to cotinine, this study expands upon previous research that relied on cotinine as an indirect indicator for nicotine intake. Our data support the hypothesis that the increased serum nicotine and cotinine levels observed are attributable to an increased nicotine intake per cigarette in smokers with schizophrenia as compared to those without mental illness.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961287     DOI: 10.1016/j.schres.2005.04.016

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  62 in total

1.  Rapid smoking may not be aversive in schizophrenia.

Authors:  Jill M Williams; Kunal K Gandhi; Shou-En Lu; Marc L Steinberg; Neal L Benowitz
Journal:  Nicotine Tob Res       Date:  2012-02-07       Impact factor: 4.244

2.  Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette.

Authors:  Jill M Williams; Kunal K Gandhi; Shou-En Lu; Supriya Kumar; Junwu Shen; Jonathan Foulds; Howard Kipen; Neal L Benowitz
Journal:  Nicotine Tob Res       Date:  2010-06-28       Impact factor: 4.244

3.  A comprehensive model for mental health tobacco recovery in new jersey.

Authors:  Jill M Williams; Mia Hanos Zimmermann; Marc L Steinberg; Kunal K Gandhi; Cris Delnevo; Michael B Steinberg; Jonathan Foulds
Journal:  Adm Policy Ment Health       Date:  2011-09

4.  Task persistence predicts smoking cessation in smokers with and without schizophrenia.

Authors:  Marc L Steinberg; Jill M Williams; Kunal K Gandhi; Jonathan Foulds; Elizabeth E Epstein; Thomas H Brandon
Journal:  Psychol Addict Behav       Date:  2012-05-28

Review 5.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

6.  Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia.

Authors:  Christopher G AhnAllen; Paul G Nestor; Martha E Shenton; Robert W McCarley; Margaret A Niznikiewicz
Journal:  Schizophr Res       Date:  2007-09-19       Impact factor: 4.939

Review 7.  Interventions for smoking cessation and reduction in individuals with schizophrenia.

Authors:  Daniel T Tsoi; Mamta Porwal; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Reasons for smoking among individuals with schizophrenia.

Authors:  Magdalena Galazyn; Marc L Steinberg; Kunal K Gandhi; Megan Piper; Jill M Williams
Journal:  Schizophr Res       Date:  2010-01-06       Impact factor: 4.939

9.  Smoking expectancies and intention to quit in smokers with schizophrenia, schizoaffective disorder and non-psychiatric controls.

Authors:  Jennifer W Tidey; Damaris J Rohsenow
Journal:  Schizophr Res       Date:  2009-12       Impact factor: 4.939

Review 10.  Reduced nicotine product standards for combustible tobacco: building an empirical basis for effective regulation.

Authors:  Eric C Donny; Dorothy K Hatsukami; Neal L Benowitz; Alan F Sved; Jennifer W Tidey; Rachel N Cassidy
Journal:  Prev Med       Date:  2014-06-23       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.